Eli Lilly and Company filed an 8-K on February 4, 2026, reporting its financial results for the quarter and year ended December 31, 2025. The filing includes a press release (Exhibit 99.
BioMarin Pharmaceutical Inc. (BMRN) announced the pricing of a $850 million private offering of 5.500% senior unsecured notes due 2034.
Regeneron Pharmaceuticals announced its fourth quarter and full year 2025 financial results, showcasing revenue growth driven by Dupixent and EYLEA HD. Q4 revenues increased 3% to $3.
Merck (MRK) reported its Q4 and full-year 2025 financial results, highlighting strong performance in oncology (driven by KEYTRUDA), animal health, and increasing contributions from newer products like...
Pfizer (PFE) released its Q4 and full-year 2025 financial results, reporting full-year revenues of $62.6 billion, a 2% operational decline year-over-year, although non-COVID product revenues grew 6%.
AbbVie reported its full-year and fourth-quarter 2025 financial results, showcasing strong growth driven by its immunology portfolio, particularly Skyrizi and Rinvoq.
Bristol Myers Squibb (BMY) reported its fourth quarter and full-year 2025 financial results, highlighting growth in its Growth Portfolio, which includes key drugs like Opdivo, Camzyos, Breyanzi, and R...
BioMarin Pharmaceutical Inc. (BMRN) announced plans to offer $850 million in senior unsecured notes due 2034 in a private offering.
Johnson & Johnson (JNJ) reported strong Q4 and full-year 2025 results, exceeding expectations with 9.1% reported sales growth in Q4 and 6.0% for the full year.